Pulmonary arterial hypertension trials in Japan

In Japan 8 Also abroad 305

8 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Where
Kitakyushu
Age
18 years to 75 years
People
135 worldwide
Run by
NS Pharma, Inc.
See details and how to joinNCT07441200 · EU 2025-525114-38-00
Phase 2Taking people
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Kitakyushu
Age
18 years to 80 years
People
177 worldwide
Run by
NS Pharma, Inc.
See details and how to joinNCT07441278
Phase 3Taking people
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Narita, Yokohama
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07234032 · EU 2025-521769-29-00
Phase 3Taking people
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Bunkyo-Ku, Chiba, Hirosaki, Kiyose, Kyotoshi, Matsumoto, Nagakute, Nagano, Narashino-shi, Narita-shi, Sakai, Sapporo, Seto, Shibuya City, Suita, Tsukuba, Yokohama
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07179380 · EU 2025-521558-40-00
Phase 3Taking people
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Where
Bunkyō City, Fukuoka, Mitaka, Nagoya, Okayama, Shinjuku-ku, Suita
Age
18 years to 75 years
People
330 worldwide
Run by
Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Where
Chiba, Kobe, Minato-ku, Mitaka-shi, Narashino, Okayama, Sapporo, Yahatanishi-ku, Kita Kyushu-shi
Age
18 years to 75 years
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07481981 · EU 2026-525265-48-00
Phase 2Taking people
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
Where
Izumi, Setagaya City, Suita
Age
1 year to 17 years
People
6
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07646860
Phase 4Taking people
A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy
Where
Fukuoka, Kobe, Kyoto, Nagoya, Okayama, Sendai, Tokyo
Age
18 years and over
People
36
Run by
Kazuya Hosokawa
See details and how to joinNCT07356778